UCB Shareholders | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Our Shareholders

Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.

The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels.

Shareholder Structure

Source

Latest notifications and shareholder identification (as of January 2022), UCB underlying ownership analysis

close

62% Free Float

Shareholders' Meetings

The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET.

The next shareholders' meeting takes place on

27 April 2023

Shareholders' Meeting Archives


 


 

Consensus

Estimates based on Visible Alpha consensus1 dated 31.01.2023.

Estimates include 11 broker models2.

UCB FY Consensus Earnings Estimates (Average)
In € million 2021a 2022e 2023e 2024e  2025e 2026e 2027e
Net Sales 5,471 5,033 4,951 5,416 6,020 6,297 6,547
Revenue 5,777 5,372 5,280 5,736 6,305 6,549 6,722
Adjusted EBIT 1,318 762 703 1,018 1,422 1,596 1,703
Adjusted EBITDA 1,641 1,189 1,161 1,502 1,919 2,104 2,229
Adj. EBITDA ratio 28.4% 22.1% 22.0% 26.2% 30.4% 32.1% 33.2%
Net Profit 1,058 517 505 789 1,155 1,285 1,344
Core EPS (€) 6.49 4.22 4.41 6.10 8.22 9.00 9.65
UCB FY Consensus Product Sales Estimates (Average)
In € million 2021a 2022e 2023e 2024e  2025e  2026e  2027e
Product Portfolio              
Cimzia 1,841 2,034 1,998 1,903 1,755 1,475 1,227
Bimzelx 4 47 207 513 875 1,218 1,578
Evenity* 10 29 67 111 148 172 193
Vimpat 1,549 1,035 568 450 379 327 305
Keppra 970 734 623 557 511 470 437
Briviact 355 465 546 614 674 544 367
Neupro 307 289 258 225 204 188 174
Fintepla   108 239 357 477 587 678
Nayzilam 57 82 112 134 151 157 162
Potential New Products              
Rozanolixizumab      27 83 170 257 334
Zilucoplan     36 130 257 375 477
Dapirolizumab pegol       25 83 164 246
Staccato alprazolam       16 27 58 89
Bepranemab         42 45 83

*European sales, ex-EU sales booked by Amgen/Astellas

1Disclaimer

The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.
Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.
In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement.

close

2Contributing brokers

Broker Model date
Berenberg 09-Jan-2023
BNPP Exane 11-Jan-2023
BofA 13-May-2022
CITI 16-Sep-2022
CS 27-Jan-2023
DB 13-Oct-2022
Jefferies 23-Jan-2022
Kepler 13-Jan-2023
MS 16-Jan-2023
ODDO 25-Dec-2022
Redburn 20-Jan-2022
close

 

Dividends

The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations.

The Board of Directors proposed to pay a gross dividend of € 1.30 per share (gross), which was approved by the annual general meeting of the shareholders.

  • Coupon # 25
  • Ex-dividend: 29 April 2022
  • Record date: 2 May 2022
  • Payment: 3 May 2022

Coupon # 25 of UCB shares is payable at € 0.91 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.

* Lower withholding tax rates may be applicable depending the specific situation of each shareholder.